ReviewCells2022
CVD and COVID-19: Emerging Roles of Cardiac Fibroblasts and Myofibroblasts.
Review in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 21 citations in OpenAlex.
- A Comprehensive Review on Cardioprotective Biological Properties of Crataegus orientalis in Post-COVID-19 Pandemic Cardiovascular Disorders.Molecular nutrition & food research · 2026Review
- Grape Seed Oil Attenuates Myocardial Fibrosis by Inhibiting the PI3K/AKT Signaling Pathway.Foods (Basel, Switzerland) · 2026Article
- Pulsed electromagnetic fields treatment ameliorates cardiac function after myocardial infarction in mice and pigs.Journal of advanced research · 2026Article
- The regulatory mechanisms and translational applications of non-coding RNA in SARS-CoV-2 infection-related cardiovascular pathology.Frontiers in cardiovascular medicine · 2026Review
- Cardiac fibrosis: from mechanisms and models to medicines.Trends in pharmacological sciences · 2025Review
- Effects of COVID-19 on the cardiovascular system: A mendelian randomization study.Sports medicine and health science · 2024Article
- Mapping the vast landscape of multisystem complications of COVID-19: Bibliometric analysis.Heliyon · 2024Article
- Review
- The impact of COVID-19 pandemic on air particulate matter exposure and heart attacks: a 5-year retrospective cohort study in Taiwan (2017-2021).Frontiers in public health · 2024Article
- Perspectives on Post-COVID-19 Pulmonary Fibrosis Treatment.Journal of personalized medicine · 2023Review
- The Eye of the Storm: Investigating the Long-Term Cardiovascular Effects of COVID-19 and Variants.Cells · 2023Review
- Rutin and quercetagetin enhance the regeneration potential of young and aging bone marrow-derived mesenchymal stem cells in the rat infarcted myocardium.Molecular and cellular biochemistry · 2023Article
- The long-term effects of the Covid-19 infection on cardiac symptoms.BMC cardiovascular disorders · 2023Observational
- Interaction of COVID-19 With Common Cardiovascular Disorders.Circulation research · 2023Review
- Long COVID: a review and proposed visualization of the complexity of long COVID.Frontiers in immunology · 2023Review
- COVID-19 is associated with the risk of cardiovascular disease death: A two-sample Mendelian randomization study.Frontiers in cardiovascular medicine · 2022Article
- SARS-CoV-2 Spike Protein Induces Oxidative Stress and Senescence in Mouse and Human Lung.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular disease (CVD) is the leading cause of death worldwide. Current data suggest that patients with cardiovascular diseases experience more serious complications with coronavirus disease-19 (COVID-19) than those without CVD. In addition, severe COVID-19 appears to cause acute cardiac injury, as well as long-term adverse remodeling of heart tissue. Cardiac fibroblasts and myofibroblasts, being crucial in response to injury, may play a pivotal role in both contributing to and healing COVID-19-induced cardiac injury. The role of cardiac myofibroblasts in cardiac fibrosis has been well-established in the literature for decades. However, with the emergence of the novel coronavirus SARS-CoV-2, new cardiac complications are arising. Bursts of inflammatory cytokines and upregulation of TGF-β1 and angiotensin (AngII) are common in severe COVID-19 patients. Cytokines, TGF-β1, and Ang II can induce cardiac fibroblast differentiation, potentially leading to fibrosis. This review details the key information concerning the role of cardiac myofibroblasts in CVD and COVID-19 complications. Additionally, new factors including controlling ACE2 expression and microRNA regulation are explored as promising treatments for both COVID-19 and CVD. Further understanding of this topic may provide insight into the long-term cardiac manifestations of the COVID-19 pandemic and ways to mitigate its negative effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.